Evidence map›Paper›PMID 32626924›Full record

ArticleInternational journal of molecular medicine2020

Rotenone restrains colon cancer cell viability, motility and epithelial‑mesenchymal transition and tumorigenesis in nude mice via the PI3K/AKT pathway.

Wenbo Xiao, Yongwei Liu, Maolin Dai, Yu Li, Renqun Peng, Shuangjiang Yu, Hao Liu

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Rotenone adaptation promotes migration and invasion of p53-wild-type colon cancer through lipid metabolism.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. OncoTargets and therapy · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wenbo XiaoDepartment of Digestion, University‑Town Hospital of Chongqing Medical University, Chongqing 401331, P.R. China.
Yongwei LiuDepartment of Infection, Rongchang District People's Hospital of Chongqing, Chongqing 402460, P.R. China.
Maolin DaiDepartment of Anesthesia, Rongchang District People's Hospital of Chongqing, Chongqing 402460, P.R. China.
Yu LiDepartment of Digestion, Rongchang District People's Hospital of Chongqing, Chongqing 402460, P.R. China.
Renqun PengDepartment of Digestion, Rongchang District People's Hospital of Chongqing, Chongqing 402460, P.R. China.
Shuangjiang YuDepartment of Neurosurgery, The First Hospital Affiliated to Army Military Medical University (Southwest Hospital), Chongqing 400038, P.R. China.
Hao LiuDepartment of Digestion, Rongchang District People's Hospital of Chongqing, Chongqing 402460, P.R. China.
Chongqing Dazu District People's Hospital · CNChongqing Medical University · CNSouthwest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rotenone, a natural hydrophobic pesticide, has been reported to display anticancer activity in a variety of cancer cells. However, the mechanism of rotenone on colon cancer (CC) cell migration, invasion and metastasis is still unknown. In the present study, the cytotoxicity of rotenone on CC cells were detected by the Cell Counting Kit‑8 assay and confirmed by clone formation assay. The effects of rotenone on CC cell invasion and migration activity were determined in vitro by Transwell invasion and wound healing assays, respectively. In addition, to reveal whether rotenone affected the epithelial‑mesenchymal‑transition (EMT) process, reverse transcription‑quantitative PCR, western blotting and immunofluorescence assays were used to detect the expression of EMT markers. The expression levels of the key markers of the PI3K/AKT pathway after rotenone treatment alone or in combination with a PI3K/AKT signaling activator in CC were also detected by western blotting. Finally, the in vivo antitumor effects of rotenone were evaluated in a subcutaneous xenotransplant tumor model treated with an intraperitoneal injection of rotenone. The results of the present study demonstrated that rotenone treatment induced CC cell cytotoxicity and greater effects were observed with increasing concentrations and inhibited cell proliferation compared with untreated cells. In vitro cell function assays revealed that rotenone inhibited CC cell migration, invasion and EMT compared with untreated cells. Mechanically, the phosphorylation levels of AKT and mTOR were downregulated in rotenone‑treated CC cells compared with untreated cells. Additionally, AKT and mTOR phosphorylation levels were increased by the PI3K/AKT signaling activator insulin‑like growth factor 1 (IGF‑1), which was reversed by rotenone treatment. The cell function assays confirmed that the IGF‑1‑activated cell proliferation, migration and invasion were decreased by rotenone treatment. These results indicated that rotenone affected CC cell proliferation and metastatic capabilities by inhibiting the PI3K/AKT/mTOR signaling pathway. In addition, rotenone inhibited tumor growth and metastatic capability of CC, which was confirmed in a xenograft mouse model. In conclusion, the present study revealed that rotenone inhibited CC cell viability, motility, EMT and metastasis in vitro and in vivo by inhibiting the PI3K/AKT/mTOR signaling pathway.

Indexed as

AnimalsBlotting, WesternCell MovementCell ProliferationCell SurvivalColonic NeoplasmsEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticMaleMiceMice, NudePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRotenoneSignal TransductionXenograft Model Antitumor AssaysPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRotenone

Identifiers

PMID32626924
PMCPMC7307809
OpenAlexW3035487361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.